Business Context and Reporting Period
This Form 8-K is a Current Report filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on January 9, 2023. The filing relates to the Company's participation in the J.P. Morgan Healthcare Conference. Reneo Pharmaceuticals is an emerging growth company incorporated in Delaware, with its principal executive offices in Irvine, California.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the availability of a corporate presentation and does not contain audited or unaudited financial statements.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The report indicates the posting of an updated corporate slide presentation on the Company's investor website.
Guidance, Outlook, and Risks
- Management Commentary: The Company posted an updated corporate slide presentation (Exhibit 99.1) in connection with the J.P. Morgan Healthcare Conference.
- Forward-Looking Statements: The Company explicitly undertakes no obligation to update, supplement, or amend the materials attached as Exhibit 99.1.
- Legal Status: The information in this report, including the presentation, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (Ticker: RPHM), not Onkure Therapeutics, Inc.
- Review the attached Exhibit 99.1 (Corporate Slide Presentation dated January 2023) for specific business updates, as the 8-K text itself contains no operational data.
- Confirm that the presentation materials are not incorporated by reference into other filings unless expressly stated.
- Note that the Company has elected emerging growth company status.